Treatment with IL-22 ameliorated steatosis and liver damage by the upregulation of anti-apoptotic and anti-oxidative genes, and the vial downregulation of lipogenic genes in hepatocytes was mediated by activation of STAT3-signaling cascade [36]. Here, IL22 is linked to steatosis.